

Eloisa Riva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4669618/publications.pdf>

Version: 2024-02-01

32
papers

708
citations

1040056

9
h-index

677142

22
g-index

32
all docs

32
docs citations

32
times ranked

1137
citing authors

#	ARTICLE	IF	CITATIONS
1	Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 295-302.	0.2	6
2	Comparative survival analysis using the International Stratification Score (ISS) in newly-diagnosed multiple myeloma in the Uruguayan population. <i>Medicine and Pharmacy Reports</i> , 2021, 94, 48-52.	0.4	0
3	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
4	Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. <i>JCO Global Oncology</i> , 2021, 7, 1151-1166.	1.8	15
5	99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 1883-1893.	1.7	6
6	Epidemiology and Risk Factors for the Development of Infectious Complications in Patients with Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America. <i>Blood</i> , 2021, 138, 3768-3768.	1.4	0
7	Epidemiological and clinical characteristics and outcome of monoclonal gammopathy of renal significance-related lesions in Latin America. <i>Nephrology</i> , 2020, 25, 442-449.	1.6	3
8	Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. <i>Leukemia and Lymphoma</i> , 2020, 61, 3112-3119.	1.3	4
9	Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. <i>GELAMM (Grupo de Estudio Latino) Tj ETQq1 1.0.784314.org/BT /O</i>	1.0	1
10	Epidemiology, Clinical Features, and Outcome of HTLV-1-Related Adult T-Cell Leukemia/Lymphoma in Latin America: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL). <i>Blood</i> , 2020, 136, 18-21.	1.4	2
11	Sars Cov-2/COVID-19 in Multiple Myeloma Latin-American Patients COVID-Lamm Study on Behalf of Gelamm (Grupo de Estudio Latino- Americano de Mieloma Múltiple). <i>Blood</i> , 2020, 136, 24-26.	1.4	0
12	Impact of Cutaneous Involvement on the Clinical Outcome of Adult T-Cell Leukemia/Lymphoma: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL). <i>Blood</i> , 2020, 136, 20-23.	1.4	0
13	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology</i> , The, 2019, 20, e302-e312.	10.7	290
14	Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e43-e50.	0.4	13
15	Real World Outcomes in Latin-American Patients with Multiple Myeloma Under 40 Years Old. <i>Blood</i> , 2019, 134, 5508-5508.	1.4	1
16	Cy7-Tocilizumab/Fab(Tocilizumab): Near Infrared Fluorescence In Vivo Imaging of Multiple Myeloma. <i>Blood</i> , 2018, 132, 5621-5621.	1.4	1
17	Development and Evaluation of a Hematology-Oriented Clinical Research Training Program in Latin America. <i>Journal of Cancer Education</i> , 2017, 32, 845-849.	1.3	3
18	Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma. <i>Oncology</i> , 2017, 92, 229-242.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Prognostication of survival and progression to dialysis in AA amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 136-137.	3.0	9
20	Tocilizumab Labeling with ^{99m} Tc via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 1267-1277.	1.7	3
21	¹⁷⁷ Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma. <i>Current Radiopharmaceuticals</i> , 2017, 10, 21-28.	0.8	6
22	A novel e8a2 BCR-ABL1 fusion with insertion of MAST2 exon 2 in a four-way translocation t (1;17;9;22) (p35;q24;q44;q11) in a patient with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 203-205.	1.3	5
23	Current imaging follow-up of non-Hodgkin lymphoma exposes patients to significant radiation but does not detect asymptomatic relapses. <i>Leukemia and Lymphoma</i> , 2016, 57, 1363-1366.	1.3	3
24	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
25	Accurate Risk Stratification Identifies Patients with AL Amyloidosis Benefiting Most from Upfront Bortezomib Combinations: A Study of Treatment Outcomes in 984 Patients. <i>Blood</i> , 2015, 126, 190-190.	1.4	5
26	Does Response to Bortezomib-Based Therapies Correlate to Beta-2 Microglobulin in Multiple Myeloma?. <i>Blood</i> , 2015, 126, 5398-5398.	1.4	0
27	^{99m} Tc-tocilizumab Fragments As Molecular Imaging Agent for Multiple Myeloma. <i>Blood</i> , 2015, 126, 4214-4214.	1.4	1
28	Real-World Data on Multiple Myeloma: A Prospective National Registry in Uruguay. <i>Blood</i> , 2015, 126, 5614-5614.	1.4	1
29	Computed Tomography Role in Limited-Stage Lymphomas: Could We Reduce the Dose of Radiation?. <i>Blood</i> , 2014, 124, 1270-1270.	1.4	0
30	Synthesis and Preliminary Assessment of ^{99m} Tc-HYNIC-Fab ^Å s (Rituximab) for Non-Hodgkin Lymphoma Diagnosis. <i>Blood</i> , 2014, 124, 5373-5373.	1.4	0
31	^{99m} Tc-Rituximab as Radiotracer For Molecular Imaging In Non Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 3026-3026.	1.4	2
32	[¹⁷⁷ Lu]DOTA-anti-CD20: Labeling and pre-clinical studies. <i>Applied Radiation and Isotopes</i> , 2011, 69, 924-928.	1.5	22